Interestingly, patients who develop mutations in the EGFR-ECD experience greater and more lasting tumor responses con anti-EGFR treatment, compare to patients who develop other mechanisms of resistance, such as RAS mutations (Van Emburgh et al., 2016). Here, EGFR is linked to neoplasm.